Last reviewed · How we verify
Daratumumab, Ixazomib, Dexamethasone
Daratumumab is a monoclonal antibody that targets CD38.
Daratumumab is a monoclonal antibody that targets CD38. Used for Multiple myeloma.
At a glance
| Generic name | Daratumumab, Ixazomib, Dexamethasone |
|---|---|
| Sponsor | Hellenic Society of Hematology |
| Drug class | Monoclonal antibody |
| Target | CD38 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Daratumumab binds to CD38 on the surface of multiple myeloma cells, marking them for destruction by the immune system.
Approved indications
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis (PHASE1)
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (PHASE3)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM (PHASE2)
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (PHASE1, PHASE2)
- Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (PHASE2)
- Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma (PHASE2)
- Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: